RecruitingPhase 2 / Phase 3NCT06926868
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Sponsor: Bristol-Myers Squibb
Hot Springs, AR · Cerritos, CA · +43 more sites